![]() |
Name |
isotalaroflavone
|
Molecular Formula | C14H12O6 | |
IUPAC Name* |
2',7-dihydroxy-5-methoxy-3'-methylspiro[2-benzofuran-3,4'-cyclopent-2-ene]-1,1'-dione
|
|
SMILES |
COc1cc(O)c2c(c1)C1(CC(=O)C(O)=C1C)OC2=O
|
|
InChI |
InChI=1S/C14H12O6/c1-6-12(17)10(16)5-14(6)8-3-7(19-2)4-9(15)11(8)13(18)20-14/h3-4,15,17H,5H2,1-2H3
|
|
InChIKey |
AVUOLDIJNVHWNL-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 276.24 | ALogp: | 1.6 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 93.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.763 |
Caco-2 Permeability: | -4.788 | MDCK Permeability: | 0.00002210 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.067 | 20% Bioavailability (F20%): | 0.049 |
30% Bioavailability (F30%): | 0.76 |
Blood-Brain-Barrier Penetration (BBB): | 0.109 | Plasma Protein Binding (PPB): | 78.97% |
Volume Distribution (VD): | 0.521 | Fu: | 11.36% |
CYP1A2-inhibitor: | 0.796 | CYP1A2-substrate: | 0.75 |
CYP2C19-inhibitor: | 0.333 | CYP2C19-substrate: | 0.418 |
CYP2C9-inhibitor: | 0.225 | CYP2C9-substrate: | 0.627 |
CYP2D6-inhibitor: | 0.104 | CYP2D6-substrate: | 0.294 |
CYP3A4-inhibitor: | 0.555 | CYP3A4-substrate: | 0.245 |
Clearance (CL): | 11.229 | Half-life (T1/2): | 0.372 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.1 |
Drug-inuced Liver Injury (DILI): | 0.541 | AMES Toxicity: | 0.176 |
Rat Oral Acute Toxicity: | 0.156 | Maximum Recommended Daily Dose: | 0.238 |
Skin Sensitization: | 0.463 | Carcinogencity: | 0.06 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.803 |
Respiratory Toxicity: | 0.364 |